Clinical trials
Phase 1/2 Ovarian Neoplasms trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2009 | 3 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 4 |
| 2021 | 5 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 13 |
| Recruiting | 12 |
| Terminated | 6 |
| Active, not recruiting | 5 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 5 |
| Incyte Corporation | 3 |
| BicycleTx Limited | 2 |
| Cancer Research UK | 2 |
| Genmab | 2 |
| Seagen Inc. | 2 |
| Aprea Therapeutics | 1 |
| Artios Pharma Ltd | 1 |
| Astellas Pharma Inc | 1 |
| BioInvent International AB | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Ovarian Neoplasms | 38 |
| Endometrial Neoplasms | 17 |
| Carcinoma, Non-Small-Cell Lung | 11 |
| Breast Neoplasms | 9 |
| Colorectal Neoplasms | 8 |
| Uterine Cervical Neoplasms | 8 |
| Triple Negative Breast Neoplasms | 7 |
| Urinary Bladder Neoplasms | 7 |
| Fallopian Tube Neoplasms | 6 |
| Prostatic Neoplasms | 6 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.